Literature DB >> 1705378

[Immunohistochemistry of cytokeratin expression in human blood vessel endothelia with special reference to synovial connective tissue].

P Stosiek1, M Kasper, K Conrad.   

Abstract

41 tissue samples derived from the synovia, epidermis, and other organs were studied immunohistochemically using monoclonal antibodies against intermediate filaments. We observed a coexpression of cytokeratin and vimentin in endothelia of small blood vessels preferably enriched in locations with enhanced fluid transport and processes of ultrafiltration via endothelial cells (synovial tissue, ganglion). The presence of cytokeratin 18 in endothelial cells has been confirmed by gel-electrophoresis with immunoblotting. In many cases, the coexpression of cytokeratin and vimentin reveals a correlation to the secretion of simply and epithelially differentiated cells as could be demonstrated for other tissue structures in previous studies. The increased expression of cytokeratins in endothelia of ganglion walls is discussed in relation to synovia-like misfunction of the joint connective tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705378

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  4 in total

1.  Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features.

Authors:  K Suda; B Rothen-Rutishauser; M Günthert; H Wunderli-Allenspach
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

2.  Cytokeratin expression in bovine corpora lutea.

Authors:  A M Ricken; K Spanel-Borowski; M Saxer; P R Huber
Journal:  Histochem Cell Biol       Date:  1995-05       Impact factor: 4.304

3.  Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease.

Authors:  D L Mattey; P T Dawes; N B Nixon; L Goh; M J Banks; G D Kitas
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

4.  Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.

Authors:  J Cummings; M Zweifel; N Smith; P Ross; J Peters; G Rustin; P Price; M R Middleton; T Ward; C Dive
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.